

# Yuki Takamatsu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1421374/publications.pdf>

Version: 2024-02-01

22  
papers

554  
citations

759233

12  
h-index

752698

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

753  
citing authors

#	ARTICLE	IF	CITATIONS
1	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. <i>Nature Communications</i> , 2021, 12, 668.	12.8	126
2	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	3.3	57
3	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. <i>MBio</i> , 2020, 11, .	4.1	52
4	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented nM to pM potency. <i>ELife</i> , 2017, 6, .	6.0	44
5	4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. <i>Hepatology</i> , 2015, 62, 1024-1036.	7.3	43
6	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. <i>Scientific Reports</i> , 2021, 11, 5563.	3.3	42
7	Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. <i>MBio</i> , 2018, 9, .	4.1	36
8	Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. <i>Oncotarget</i> , 2017, 8, 50342-50358.	1.8	28
9	The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. <i>Cell Chemical Biology</i> , 2018, 25, 1268-1278.e3.	5.2	20
10	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	3.4	18
11	Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. <i>ChemMedChem</i> , 2019, 14, 1863-1872.	3.2	16
12	C-5-Modified Tetrahydropyrano-Tetrahydrofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. <i>Journal of Virology</i> , 2016, 90, 2180-2194.	3.4	15
13	Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
14	GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	8
15	Synthesis of 4'-Substituted Purine 2'-Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. <i>ChemistrySelect</i> , 2018, 3, 3313-3317.	1.5	6
16	A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. <i>Global Health &amp; Medicine</i> , 2019, 1, 36-48.	1.4	5
17	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. <i>GHM Open</i> , 2022, 2, 38-43.	0.6	4
18	Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 991-994.	1.7	4

#	ARTICLE	IF	CITATIONS
19	A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy. <i>International Journal of Infectious Diseases</i> , 2022, 121, 85-88.	3.3	4
20	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). <i>Life</i> , 2022, 12, 856.	2.4	4
21	Novel 4'-modified nucleoside analogs exert antiviral replication against hepatitis B virus with drug resistance mutations. <i>Acta Hepatologica Japonica</i> , 2016, 57, 299-301.	0.1	0
22	A familial cluster of severe coronavirus disease 2019 that required intubation of all family members. <i>Infectious Diseases</i> , 2020, 52, 755-758.	2.8	0